Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

7 results about "Dextran Sulfate Sodium" patented technology

Treatment with dextran sulfate sodium triggers development of colitis in mice and rats by binding to medium-chain-length fatty acids present in the colon and inducing inflammation. General description Dextran is a polymer of anhydroglucose. It is composed of approximately 95% alpha-D-(166) linkages.

Use of castanea mollissima blume total involucre alcohol extract in preparing a drug for treating colitis

PendingCN122321013ACytotoxicitySteatoda castanea
This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.
Owner:GUIZHOU UNIV

Composition comprising bentonite as active ingredient for preventing, alleviating, or treating intestinal fibrosis

PCT designated stageWO2026116950A1Digestive systemAccessory food factorsFibrosisDisease activity
The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.
Owner:KOREA INST OF ORIENTAL MEDICINE +1

Method for preparing high-value cellobiose from a medicinal and edible aesculus chinensis residue and application thereof

PendingCN122326697ABiotechnologyDisease
The application discloses a method for preparing high-value cellobiose from a medicine and food homologous Radix Millettiae and application of the high-value cellobiose. The method comprises the following steps: extracting cellulose from Radix Millettiae; optimizing a beta-glucanase enzymolysis process by using a response surface method; after the enzymolysis liquid is subjected to selective removal of glucose through yeast fermentation, the high-value cellobiose product is obtained through acetone precipitation and freeze-drying. The process condition is mild and environment-friendly, high-value utilization of agricultural waste is realized, the obtained cellobiose product has high purity, and an economic and effective approach is provided for large-scale production of cellobiose. Animal experiments prove that the cellobiose product has a significant relieving effect on colonitis induced by dextran sulfate sodium in mice, can effectively improve disease symptoms, reduce oxidative stress, repair intestinal barrier and regulate inflammatory response, and has a good application prospect in preparation of functional food or medicine for relieving colonitis and high-value utilization of Radix Millettiae.
Owner:SOUTH CHINA UNIV OF TECH

Composition comprising zeolite as active ingredient for preventing, alleviating, or treating depression or anxiety disorder

The present invention relates to a composition for preventing, alleviating, or treating depression or anxiety disorder, the composition comprising a zeolite as an active ingredient, wherein the zeolite is excellent in increasing activity by alleviating depression or anxiety disorder in open-field tests and light-dark tests using a colitis animal model induced by dextran sulfate sodium salt (DSS), and is thus expected to be useful as a composition for preventing, alleviating, or treating depression or anxiety disorder.
Owner:KOREA INST OF ORIENTAL MEDICINE +1

Use of aescin in the preparation of a drug for preventing and treating ulcerative colitis

The application relates to the technical field of ulcerative colitis prevention and treatment, and particularly relates to application of avicularin in preparation of ulcerative colitis prevention and treatment drugs. Avicularin can effectively improve ulcerative colitis of mice caused by dextran sulfate sodium (DSS), can not only improve colon injury and reduce DAI index, but also can reduce expression of inflammatory cytokines and increase expression of intestinal mucosal barrier related proteins.
Owner:ZHANGJIAGANG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Composition comprising zeolite as active ingredient for preventing, alleviating, or treating intestinal fibrosis

The present invention relates to a composition for preventing, alleviating, or treating intestinal fibrosis, the composition comprising zeolite as an active ingredient. The zeolite according to the present invention is highly effective in reducing the thickness of intestinal tissue and the accumulation of collagen in intestinal tissue and reducing the expression level of a gene related to fibrosis in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of an ɑ-smooth muscle actin (ɑ-SMA) protein in an intestinal fibrosis cell model induced by TGF-β.
Owner:KOREA INST OF ORIENTAL MEDICINE +1